Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) CEO Ivan Bergstein purchased 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were purchased at an average cost of $11.05 per share, with a total value of $22,100.00. Following the completion of the purchase, the chief executive officer now directly owns 1,903,955 shares in the company, valued at approximately $21,038,703. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Stemline Therapeutics (NASDAQ:STML) traded down 0.27% on Wednesday, hitting $10.92. 142,012 shares of the company’s stock traded hands. Stemline Therapeutics has a 1-year low of $10.509 and a 1-year high of $47.25. The stock has a 50-day moving average of $11.66 and a 200-day moving average of $16.40. The company’s market cap is $141.4 million.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.39 earnings per share for the current fiscal year.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.